Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewTH 588 is a potent MTH1 inhibitor (IC50 = 5 nM). Induces oxidative DNA damage and reduces survival in cancer cells. Inhibits growth of breast and colorectal cancer xenografts in mice.
Sold under license from Thomas Helleday's Foundation for Medical Research and Oxcia AB.
分子量 | 295.17 |
公式 | C13H12Cl2N4 |
储存 | Store at -20°C |
纯度 | ≥98% (HPLC) |
CAS Number | 1609960-31-7 |
PubChem ID | 73389731 |
InChI Key | PNMYJIOQIAEYQL-UHFFFAOYSA-N |
Smiles | NC1=NC(C2=C(Cl)C(Cl)=CC=C2)=CC(NC3CC3)=N1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Gad et al (2014) MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature 508 215 PMID: 24695224
关键词: TH 588, TH 588 supplier, TH588, MTH1, MutT, homolog-1, inhibitors, inhibits, potent, NUDT1, (MTH1), 5334, Tocris Bioscience
目前没有该产品的评论。 Be the first to review TH 588 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.
This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.